Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Gemcitabine 9Docetaxel 8Androgen Antagonists 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6Magnetic Resonance Spectroscopy 6gallium 68 PSMA-11 5Prednisone 5Leuprolide 5Goserelin 5Cisplatin 5enzalutamide 4bicalutamide 4Triptorelin Pamoate 4Radiosurgery 4Carboplatin 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4luprolide acetate gel depot 3Flutamide 3Celecoxib 3valrubicin 2pembrolizumab 2nilutamide 2cabazitaxel 2abiraterone 2Zoledronic Acid 2Vinblastine 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × ALT-803 × Genitourinary × Clear all
NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 2/3 Active not recruiting
190 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡